GT BIOPHARMA, INC. Related Party Transaction, Expenses from Transactions with Related Party
GT BIOPHARMA, INC. (GTBP) reported Related Party Transaction, Expenses from Transactions with Related Party of $350.00 thousand for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty · last filed 2021-12-29
- GT BIOPHARMA, INC. related party transaction, expenses from transactions with related party for the quarter ending 2021-09-30 was $100.00K.
- GT BIOPHARMA, INC. related party transaction, expenses from transactions with related party for the quarter ending 2021-06-30 was $0.00.
- GT BIOPHARMA, INC. related party transaction, expenses from transactions with related party for the quarter ending 2021-03-31 was $250.00K.
- GT BIOPHARMA, INC. related party transaction, expenses from transactions with related party for fiscal 2019 was $1.14M.
| Period end | Related Party Transaction, Expenses from Transactions with Related Party 3 month | Related Party Transaction, Expenses from Transactions with Related Party 6 month | Related Party Transaction, Expenses from Transactions with Related Party 9 month | Related Party Transaction, Expenses from Transactions with Related Party 12 month | Related Party Transaction, Expenses from Transactions with Related Party 12 month as first filed |
|---|---|---|---|---|---|
| 2021-09-30 | $100.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2021-11-10 | $100.00K derived: sum of 2 quarters · filed 2021-12-29 | $350.00K 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q 3 month · filed 2021-12-29 | $250.00K 10-Q/A · filed 2021-12-29 | |||
| 2021-03-31 | $250.00K 10-Q · filed 2021-05-17 | ||||
| 2020-12-31 | $525.00K 10-Q · filed 2021-11-10 | $1.13M 10-K · filed 2021-04-16 | |||
| 2020-06-30 | $525.00K 10-Q/A · filed 2021-12-29 | ||||
| 2019-12-31 | $1.14M 10-K · filed 2021-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |